Page 13 - <>期刊 v2

13
Back ID D N U | iddnu@suntrap.com | www.suntrap.com

Clinical Evaluation of LeSoleil Against COVID-19

Announcement on Global Recruitment of Collaborative Agencies for LeSoleil

Since February 2020, Suntrap Life Technologies Ltd. has prudently evaluat-
ed and predicted the characteristics of COVID-19. A Suntrap research team
was immediately established and the project for the drug discovery against
COVID-19 was launched. Utilizing the self-built S-CPDD drug design and dis-
covery system and IDDNU® (International Drug Design Network Union) plat-
forms that are constructed in accordance with scientific laws of drug discovery, Suntrap’s research team fully tracked and analyzed the
pathological characteristics, clinical needs, pathogenesis research and social demands of patients. In terms of the determination of the di-
rection of drug research and development (R&D), COVID-19 drug related targets acquisition, molecular design and screening, and preclinical
verification, the new drug R&D in the Suntrap research team is fully guided by clinical values. It will be a standard for the Suntrap team that
can quickly transform biomedical research into industrial products, and ultimately develop new pharmaceutical products that benefit the
public, thus realizing the fundamental significance of new drug R&D.

Suntrap’s team believes that the prevention and treatment of COVID-19 should focus on the development of multi-targeted
and broad-spectrum anti-coronavirus drugs.

An AI-assisted drug design module in the self-developed IDDNU® In May 2020, the Suntrap research team identified a lead com-
platform was employed to balance the interactions among SARS- pound “LeSoleil-T” through a series of bioassays, which showed
CoV-2 related drug targets. In addition, various virtual screening anti-coronavirus activities with multi-targets inhibition effects.
modules including ADMET (drug absorption, distribution, metab- Further studies revealed that the multi-targets design properties
olism, excretion, and toxicity) properties prediction, targets and of LeSoleil-T could meet the demands of broad-spectrum an-
SARS-CoV-2 infection cell model-based inhibition activity pre- ti-coronavirus.
diction were combined to screen Suntrap’s self-built clinical and
In August 2020, the Guangdong Provincial Institute of Public
drug-related data resource library, and then quickly select poten-
Health (also known as Guangdong Provincial Center for Disease
tial compounds with good anti-COVID-19 activity and low toxicity.
Control and Prevention) was commissioned to investigate the sen-
These potential molecules were then subjected to cell-based phe-
sitivity of SARS-CoV-2 to “LeSoleil-T (莱素理)”. The results showed
notypic antiviral screening testing.
that (1) LeSoleil-T has low toxicity with a TC value of 121.06 μg/
50